Repligen Corp (RGEN) — SEC Filings
Repligen Corp (RGEN) — 36 SEC filings. Latest: 8-K (May 5, 2026). Includes 16 8-K, 8 SC 13G/A, 5 10-Q.
View Repligen Corp on SEC EDGAR
Overview
Repligen Corp (RGEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: REPLIGEN CORP (RGEN) reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased to $188.805 million from $154.871 million in the prior year, a 21.9% increase. Net income for the three months surg
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 32 neutral. The dominant filing sentiment for Repligen Corp is neutral.
Filing Type Overview
Repligen Corp (RGEN) has filed 16 8-K, 5 10-Q, 2 DEFA14A, 2 DEF 14A, 2 10-K, 1 10-K/A, 8 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of RGEN's 28 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $540.3M |
| Net Income | $35.6M |
| Cash Position | $748.7M |
Key Executives
- Tony J. Hunt
- Catherine M. Davis
- Walter J. DeGrange, Jr.
- Dr. Paul J. Hastings
- Ms. Sarah E. Emrey
- Dr. Jonathan M. Rothberg
Industry Context
Repligen operates in the life sciences industry, focusing on bioprocessing technologies. The sector is characterized by innovation, significant R&D investment, and a complex regulatory environment. Key trends include the growing demand for biologics, the need for efficient and scalable manufacturing solutions, and increasing consolidation through mergers and acquisitions.
Top Tags
financials (5) · financial-reporting (4) · 8-k (4) · amendment (4) · acquisition (4) · results-of-operations (3) · governance (3) · Repligen Corp (3) · institutional-ownership (3) · Bioprocessing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Total Revenue | $188.8M | Up 21.9% from $154.9M in Q3 2024, indicating strong product sales growth. |
| Q3 2025 Net Income | $14.9M | A significant turnaround from a $0.7M net loss in Q3 2024, demonstrating improved profitability. |
| YTD 2025 Total Revenue | $540.3M | Increased 15.7% from $466.9M in YTD 2024, reflecting sustained growth. |
| YTD 2025 Net Income | $35.6M | A 326% increase from $8.4M in YTD 2024, highlighting substantial profit expansion. |
| Goodwill | $1.11B | Increased from $1.03B at December 31, 2024, suggesting recent strategic acquisitions. |
| YTD 2025 Cash from Operations | $91.7M | Decreased from $136.2M in YTD 2024, indicating a potential shift in operational cash efficiency despite higher net income. |
| YTD 2025 Cash Used in Investing | $89.7M | Increased significantly from $21.6M in YTD 2024, primarily due to acquisitions net of cash acquired. |
| Cash and Cash Equivalents | $748.7M | Slightly decreased from $757.4M at the beginning of the period, reflecting investment activities. |
| SEC File Number | 000-14656 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 04-2729386 | Tax identification number for the company. |
| Q2 2025 Revenue | $150.5M | down 15.2% from Q2 2024 |
| Q2 2025 Net Income | $4.2M | down 85.7% from Q2 2024 |
| Q2 2025 Diluted EPS | $0.07 | significant drop from $0.49 in Q2 2024 |
| Revenue Decrease | 15.2% | year-over-year decline in Q2 2025 |
| Net Income Decrease | 85.7% | year-over-year decline in Q2 2025 |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Repligen Corp.","entity":"The Vanguard Group","targetDate":"December 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Repligen Corp (RGEN)?
Repligen Corp has 36 recent SEC filings from Jan 2024 to May 2026, including 16 8-K, 8 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RGEN filings?
Across 36 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 32 neutral. The dominant sentiment is neutral.
Where can I find Repligen Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Repligen Corp (RGEN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Repligen Corp?
Key financial highlights from Repligen Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RGEN?
The investment thesis for RGEN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Repligen Corp?
Key executives identified across Repligen Corp's filings include Tony J. Hunt, Catherine M. Davis, Walter J. DeGrange, Jr., Dr. Paul J. Hastings, Ms. Sarah E. Emrey and 1 others.
What are the main risk factors for Repligen Corp stock?
Of RGEN's 28 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Repligen Corp?
Recent forward-looking statements from Repligen Corp include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Repligen Corp.","entity":"The Vanguard Group","targetDa.